Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • P108: Integrating baseline cir...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
P108: Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma

P108: Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma

Bibliographic Details
Main Authors: Eleonora Calabretta, Martina Di Trani, Martina Sollini, Francesca Ricci, Francesco Corrado, Vanessa Cristaldi, Stefanos Bonovas, Fabrizio Marino, Rita Mazza, Lodovico Terzi Di Bergamo, Alessio Bruscaggin, Maria Cristina Pirosa, Stefania Bramanti, Arturo Chiti, Armando Santoro, Davide Rossi, Carmelo Carlo-Stella
Format: Article
Language:English
Published: Wiley 2022-10-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000891000.99990.30
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000891000.99990.30

Similar Items

  • P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
    by: Chiara Rusconi, et al.
    Published: (2022-10-01)
  • The immune cell dynamics in the peripheral blood of cHL patients receiving anti-PD1 treatment
    by: Vanessa Cristaldi, et al.
    Published: (2025-03-01)
  • S225: CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER AT BASELINE AND IMPROVES THE ACCURACY OF INTERIM PET IN CLASSIC HODGKIN LYMPHOMA
    by: M. C. Pirosa, et al.
    Published: (2022-06-01)
  • Asymptomatic versus symptomatic patients: [18F]FDG-PET/CT patterns and evolutionary track of COVID-19 associated vasculitis
    by: Martina Sollini, et al.
    Published: (2021-02-01)
  • Analysis of Prognostic Factors in 108 Patients with Non-Hodgkin’s Lymphoma
    by: Jia-ming TANG, An-wei CHEN, Wen-ming PENG, et al.
    Published: (2010-02-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs